Scilex Pharmaceuticals News and Activities

Scilex Pharmaceuticals is owned by Sorrento Therapeutics.

Sorrento Therapeutics is a company listed under the stock ticker SRNE (US).

View the org chart displaying its 12 main executives

Most searched biographies at Scilex Pharmaceuticals

• Jay Chun, Director
• Dorman Followwill, Director
• Henry Ji, Chairman of the Board

Create your alert
to follow the executive moves at Scilex Pharmaceuticals.

Sorrento Therapeutics has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott
• Jonathan Leff - Director at Larimar Therapeutics

Learn more about the Pharmaceuticals industry

Press releases by Scilex Pharmaceuticals

• News & Events – Scilex Holding
• News & Events - Scilex Holding
• News - Scilex Holding
• Scilex Announces Addition of ZTlido® to Express Scripts National Formularies - Scilex Holding
• Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary Announces Expansion of Ztlido® Managed Care Coverage for Additional 33 Million Lives – SCILEX Pharmaceutical
• Scilex Holding Company, a Sorrento Company, Announces Complete Enrollment on Non-Opioid Injectable SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program For Sciatica Pain Management – SCILEX Pharmaceutical
• Scilex Holding, A Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for Ztlido® Label Expansion – SCILEX Pharmaceutical
• Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndr
• Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido® and Expects to Complete Enrollment on its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial Program in 2020 – SCILEX Pharmaceutical
• Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released – SCILEX Pharmaceutical
• View more press releases Close

Social media about Scilex Pharmaceuticals

• Scilex Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Scilex Pharmaceuticals on LinkedIn, X (Twitter) & YouTube